AlloVir Inc (NAS:ALVR)
$ 0.457 -0.0161 (-3.4%) Market Cap: 54.67 Mil Enterprise Value: -67.05 Mil PE Ratio: 0 PB Ratio: 0.45 GF Score: 29/100

Allovir Inc at JPMorgan Healthcare Conference Transcript

Jan 10, 2023 / 10:15PM GMT
Release Date Price: $5.37 (+5.92%)
Anupam Rama
JPMorgan Chase & Co, Research Division - VP and Analyst

Thanks, everyone. Welcome to the Tuesday afternoon session of the 41st Annual JPMorgan Healthcare Conference. My name is Anupam Rama. I'm one of the senior biotech analysts here at JPMorgan. I'm joined by my colleagues, Malcolm Kuno and Priyanka Grover. Our next presenting company is AlloVir, and presenting on behalf of the company, we have CEO, Diana Brainard.

Diana M. Brainard
AlloVir, Inc. - CEO & Director

Thanks, Anupam, and thanks to everyone for being in the room today and on the line. It's really nice to be in person and looking at a group of real people. I'm -- you're real, right? I'm really happy to be providing an update on AlloVir and the excellent progress we've made over the last year and talk about where we're headed in 2023 and beyond.

As a starting point, we're a platform company developing allogeneic, off-the-shelf, virus-specific T cell therapies to address life-threatening viral diseases through either treatment or prevention in immunocompromised patients.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot